↓ Skip to main content

TGF-β in pancreatic cancer initiation and progression: two sides of the same coin

Overview of attention for article published in Cell & Bioscience, August 2017
Altmetric Badge

Citations

dimensions_citation
95 Dimensions

Readers on

mendeley
133 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
TGF-β in pancreatic cancer initiation and progression: two sides of the same coin
Published in
Cell & Bioscience, August 2017
DOI 10.1186/s13578-017-0168-0
Pubmed ID
Authors

Wei Shen, Guo-qing Tao, Yu Zhang, Bing Cai, Jian Sun, Zhi-qiang Tian

Abstract

Pancreatic cancer is highly lethal malignant tumor with characterised rapid progression, invasiveness and resistance to radiochemotherapy. Transforming growth factor-β (TGF-β) signaling plays a dual role in both pro-tumorigenic and tumor suppressive of pancreatic cancer, depending on tumor stage and microenvironment. TGF-β signaling components alteration are common in pancreatic cancer, and its leading role in tumor formation and metastases has received increased attention. Many therapies have investigated to target TGF-β signaling in the preclinical and clinical setting. In this review, we highlight the dual roles of TGF-β and touch upon the perspectives on therapeutic target of TGF-β signaling in pancreatic cancer.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 133 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 133 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 23 17%
Student > Master 23 17%
Student > Bachelor 18 14%
Student > Doctoral Student 11 8%
Researcher 8 6%
Other 14 11%
Unknown 36 27%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 42 32%
Medicine and Dentistry 18 14%
Agricultural and Biological Sciences 16 12%
Pharmacology, Toxicology and Pharmaceutical Science 5 4%
Immunology and Microbiology 4 3%
Other 6 5%
Unknown 42 32%